BD HorizonTM BV421 Mouse Anti-Human IL-33 Receptor (ST2)

Description

Flow cytometric analysis of IL-33 Receptor ST2 expression on KU812 cells. Cells from the Human KU812 Chronic Myelogenous Leukemia, ATCC CRL-2099 cell line were cultured in the presence Left Plot or absence of serum Right Plot for 6 days. The cells were then preincubated with Human BD Fc Block Cat. No. 564219/564220 and stained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; dashed line histograms or BD Horizon BV421 Mouse Anti-Human IL-33 Receptor ST2 antibody Cat. No. 569426/569427; solid line histograms . BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The fluorescence histograms showing IL-33 Receptor ST2 expression or Ig Isotype control staining were derived from gated events with the forward and side light-scatter characteristics of viable 7-AAD-negative cells. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Flow cytometric analysis of IL-33 Receptor ST2 expression on KU812 cells. Cells from the Human KU812 Chronic Myelogenous Leukemia, ATCC CRL-2099 cell line were cultured in the presence Left Plot or absence of serum Right Plot for 6 days. The cells were then preincubated with Human BD Fc Block Cat. No. 564219/564220 and stained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; dashed line histograms or BD Horizon BV421 Mouse Anti-Human IL-33 Receptor ST2 antibody Cat. No. 569426/569427; solid line histograms . BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The fluorescence histograms showing IL-33 Receptor ST2 expression or Ig Isotype control staining were derived from gated events with the forward and side light-scatter characteristics of viable 7-AAD-negative cells. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Flow cytometric analysis of IL-33 Receptor ST2 expression on KU812 cells. Cells from the Human KU812 Chronic Myelogenous Leukemia, ATCC CRL-2099 cell line were cultured in the presence Left Plot or absence of serum Right Plot for 6 days. The cells were then preincubated with Human BD Fc Block Cat. No. 564219/564220 and stained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; dashed line histograms or BD Horizon BV421 Mouse Anti-Human IL-33 Receptor ST2 antibody Cat. No. 569426/569427; solid line histograms . BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The fluorescence histograms showing IL-33 Receptor ST2 expression or Ig Isotype control staining were derived from gated events with the forward and side light-scatter characteristics of viable 7-AAD-negative cells. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Show More Flow cytometric analysis of IL-33 Receptor ST2 expression on KU812 cells. Cells from the Human KU812 Chronic Myelogenous Leukemia, ATCC CRL-2099 cell line were cultured in the presence Left Plot or absence of serum Right Plot for 6 days. The cells were then preincubated with Human BD Fc Block Cat. No. 564219/564220 and stained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; dashed line histograms or BD Horizon BV421 Mouse Anti-Human IL-33 Receptor ST2 antibody Cat. No. 569426/569427; solid line histograms . BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The fluorescence histograms showing IL-33 Receptor ST2 expression or Ig Isotype control staining were derived from gated events with the forward and side light-scatter characteristics of viable 7-AAD-negative cells. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Show More Flow cytometric analysis of IL-33 Receptor ST2 expression on KU812 cells. Cells from the Human KU812 Chronic Myelogenous Leukemia, ATCC CRL-2099 cell line were cultured in the presence Left Plot or absence of serum Right Plot for 6 days. The cells were then preincubated with Human BD Fc Block Cat. No. 564219/564220 and stained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; dashed line histograms or BD Horizon BV421 Mouse Anti-Human IL-33 Receptor ST2 antibody Cat. No. 569426/569427; solid line histograms . BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The fluorescence histograms showing IL-33 Receptor ST2 expression or Ig Isotype control staining were derived from gated events with the forward and side light-scatter characteristics of viable 7-AAD-negative cells. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Flow cytometric analysis of IL-33 Receptor ST2 expression on KU812 cells. Cells from the Human KU812 Chronic Myelogenous Leukemia, ATCC CRL-2099 cell line were cultured in the presence Left Plot or absence of serum Right Plot for 6 days. The cells were then preincubated with Human BD Fc Block Cat. No. 564219/564220 and stained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; dashed line histograms or BD Horizon BV421 Mouse Anti-Human IL-33 Receptor ST2 antibody Cat. No. 569426/569427; solid line histograms . BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The fluorescence histograms showing IL-33 Receptor ST2 expression or Ig Isotype control staining were derived from gated events with the forward and side light-scatter characteristics of viable 7-AAD-negative cells. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software.